Skip to content
Pharma Observatory a Scientist.com platform

Organization (Other)

Johnson & Johnson Consumer Inc. (J&JCI)

ClinicalTrials.gov lists Johnson & Johnson Consumer Inc. (J&JCI) as lead sponsor of 55 trials. It has 9 active development programs and 9 approved assets.

Manufacturer Other
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

12 0 2014 2027

Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.

2026 is partial: 0 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 1 in 2026 and about 2 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (5 to 20), forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

This page covers Johnson & Johnson Consumer Inc. (J&JCI): 55 lead-sponsored trials and 0 legal-entity registrations. Part of KENVUE INC..

Get the Johnson & Johnson Consumer Inc. (J&JCI) report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Disease areas (17)

Shown in this order: most trials first.

Disease areas
Disease area Trials
Dermatitis, Atopic 8
Acne Vulgaris 4
Eczema 4
Gingivitis 4
Plaque, Amyloid 3

Trials by start year as sponsor or collaborator (12)

Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Show the table of trials by start year as sponsor or collaborator
Trials by start year as sponsor or collaborator
Year Trials started
2025 1
2024 5
2023 10
2022 6
2021 12
2020 3
2019 4
2018 3
2017 8
2016 1

Recruitment duration, a model prediction: none of the 55 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

Active development programs (9)

Shown in this order: max phase, then active trials.

Active development programs
Drug Disease area Max phase Trials
Acetaminophen/Naproxen Sodium Fixed Combination Pain Phase 3 2
Acetaminophen/Naproxen Sodium Fixed Combination Toothache Phase 3 1
Acetaminophen Facial Pain Phase 3 1
Acetaminophen Pain Phase 3 1
Acetaminophen Toothache Phase 3 1

Approved assets (9)

Shown in this order: max phase first.

Approved assets
Drug Trials
Colgate Cavity Protection Toothpaste 12
LISTERINE COOL MINT Antiseptic Mouthwash 5
Listerine Total Care Zero 1
LISTERINE ZERO Alcohol Mouthwash COOL MINT 1
Listerine Total Care Zero Alcohol Mouthwash 1

Sponsor delivery record (1)

Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.

Sponsor delivery record
Enrollment Timeline
54% hit target (n=26) 46% on time (n=24)

Journals published in (125)

Shown in this order: most published in first.

Journals published in
Journal Publications
The Journal of allergy and clinical immunology 12
BMC oral health 5
Journal of drugs in dermatology : JDD 5
The British journal of dermatology 5
Archives of dermatology 4

US granted patents (1)

Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.

US granted patents
US patents granted Granted in the last 5 years Most recent grant
746 155 2025-03-04

Organization relationships (2)

Shown in this order: most evidence first.

Organization relationships
Related organization Relationship Evidence
CuddleBright Cares Co sponsors trial with 1
Saint Joseph's University, Philadelphia Co sponsors trial with 1

Latest dated events (803)

Shown in this order: newest first.

Latest dated events
Date Event Source
2025-03-04 Patent granted Granted US patents (PatentsView / USPTO)
2025-01-20 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2025-01-07 Patent granted Granted US patents (PatentsView / USPTO)
2024-12-31 Patent granted Granted US patents (PatentsView / USPTO)
2024-12-24 Patent granted Granted US patents (PatentsView / USPTO)

Biomarker capability evidence (16)

Shown in this order: tier desc, then gene symbol.

Biomarker capability evidence
Gene Role Evidence
PHLDA2 Trial sponsor Named in trial inclusion criteria
TPI1 Trial sponsor Named in trial inclusion criteria
TPI1 Trial sponsor Named in trial inclusion criteria
TPI1 Trial sponsor Named in trial inclusion criteria
ISM1 Trial sponsor Named in trial exclusion criteria

Not on this page

Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.